T-I-H-I / Shutterstock.com
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Abundant Natural Health is developmenting a program which will focus on Australian and international distribution, brand awareness, and sales of its expanding magnesium product range.

Recently, ANH has secured two major Australian pharmacies to stock its products, with an emphasis on its magnesium-based range. ANH’s magnesium products sit on the shelves on 500 stores across Australia with the company focusing to increase this number to 5,000. 

ANH intends to invest in marketing strategies in order to increase coverage. These can include taking on brand ambassadors and optimising social media promotion. ANH attended China’s International Import Expo last November.

Representatives from Chinese distributors and Daigou groups expressed a strong interest in establishing a commercial relationship with ANH. For the remainder of 2019, ANH will rely on Daigou shoppers and the distribution in specialist pharmacies, gift shops and increased engagement with Asian social media.

In order to achieve this, a new Chinese website has been launched by the company. ANH will expand its magnesium product range and is focusing on developing magnesium lotion, bath sachets, a hand cream, and foot lotion.

This range is expected to appeal to the 175 million global sufferers of psoriasis, and 245 million sufferers of eczema/dermatitis. “By the end of the calendar year, we expect ANH will be selling six to eight natural magnesium and salt products across Australia and into China,” General Manager Shanan Birkin said.

Click here to view the full announcement

ABT by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…